Quentin Chambers
Psychiatric/Mental Health · Des Moines, IANPI 1750794319
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $26,675 of the $39,628 with a category attached, or 67.3%. AbbVie accounts for 79.7% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2021 at $26,520 and has fallen 90.1% since, to $2,623 in 2025. Among psychiatric/mental health clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 448 payments — averaging $88.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$32K
- Neurocrine Biosciences, Inc.$1K
- Teva Pharmaceuticals USA, Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$928
- Takeda Pharmaceuticals U.S.A., Inc.$831
- Alkermes, Inc.$765
- plus $3K from 14 others
What the payments were for
- Speaking & faculty fees$26,67567%
- Travel & lodging$3,5359%
- Food & beverage$9,33224%
- Education$870%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 108 | $31,565 |
| Neurocrine Biosciences, Inc. | 30 | $1,112 |
| Teva Pharmaceuticals USA, Inc. | 48 | $1,103 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 29 | $928 |
| Takeda Pharmaceuticals U.S.A., Inc. | 49 | $831 |
| Alkermes, Inc. | 19 | $765 |
| Vanda Pharmaceuticals Inc. | 25 | $678 |
| E.r. Squibb & Sons, L.L.C. | 31 | $580 |
| Otsuka America Pharmaceutical, Inc. | 23 | $390 |
| Jazz Pharmaceuticals Inc. | 20 | $327 |
| Johnson & Johnson | 13 | $285 |
| Axsome Therapeutics, Inc. | 6 | $216 |
| Lundbeck LLC | 8 | $175 |
| Sunovion Pharmaceuticals Inc. | 10 | $160 |
| Indivior Inc. | 9 | $136 |
| Merck | 7 | $131 |
| Supernus Pharmaceuticals, Inc. | 7 | $121 |
| Almatica Pharma LLC | 4 | $89 |
| Corium, LLC | 1 | $22 |
| Collegium Pharmaceutical, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$39,628 in reported general payments places this provider in the 95th percentile of 443 psychiatric/mental health providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 70 | $95,557 |
| TrintellixVortioxetine Hydrobromide | 157 | $69,079 |
| Invega SustennaPaliperidone Palmitate | 18 | $39,374 |
| VivitrolNaltrexone Microspheres | 13 | $22,040 |
| CaplytaLumateperone Tosylate | 12 | $20,737 |
| NuedextaDextromethorphan Hbr/Quinidine | 14 | $10,271 |
| BelsomraSuvorexant | 30 | $7,772 |
| Lurasidone Hcl | 45 | $6,661 |
| Olanzapine OdtOlanzapine | 40 | $4,310 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 21 | $3,641 |
| Paliperidone ErPaliperidone | 26 | $3,635 |
| Modafinil | 12 | $3,278 |
| Aripiprazole | 46 | $2,505 |
| Memantine Hcl ErMemantine Hcl | 14 | $1,761 |
| Clonazepam | 92 | $1,724 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $31,565 | $95,55770 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $831 | $69,079157 claims |
| Johnson & JohnsonInvega Sustenna | $285 | $39,37418 claims |
| Alkermes, Inc.Vivitrol | $765 | $22,04013 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $928 | $20,73712 claims |
| MerckBelsomra | $131 | $7,77230 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 443 psychiatric/mental health providers in Iowa.
Other psychiatric/mental health in Des Moines
- Cynthia CoenenDes Moines$8K
- Rachel FilzerDes Moines$5K
- Tarrah HollidayAtlantic$421K
- Kelsie SwisherParkersburg$235K
- Jennifer BradleyCedar Rapids$66K
- Kama AusbornWaterloo$64K
- Tenaea JeppesonFort Dodge$38K
- Jennifer WittmanCoralville$25K
- Amy MorinCedar Rapids$24K
- Jenna BerendzenCedar Falls$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.